Consistent with the results of these studies, we determined that HCC patients with high Nanog-CTC content had a shorter progression-free survival period and proposed that Nanog be included as a marker for measuring liver cancer metastasis. The gene discussed is NANOG; the disease is hepatocellular carcinoma.